PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

about

Distinct DNA Methylation Profiles in Ovarian Tumors: Opportunities for Novel Biomarkers.Tumor evolution and chemoresistance in ovarian cancer Rapid detection of copy number variations and point mutations in genes using a single workflow by ion semiconductor sequencing pipeline

P2860

Q55629563-3CD8D0B7-995A-48B8-918A-A342B69B44A6 Q58733743-AC9C29D4-4D44-4697-883C-5603A5015B71 Q58739875-CE13DBC8-9868-4749-A1F2-C468EAD1DE1E

P2860

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

Item

http://www.wikidata.org/entity/Q49723005

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

@en

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

@nl

type

Item

label

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

@en

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

@nl

prefLabel

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

@en

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

@nl

P1476

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

@en

P2093

Andrew R Clamp

http://www.w3.org/2001/XMLSchema#string

Richard J Edmondson

http://www.w3.org/2001/XMLSchema#string

Robert D Morgan

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

The role of poly(ADP-ribose) in the DNA damage signaling network

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Integrated genomic analyses of ovarian carcinoma

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

P2888

s00280-018-3532-9

P304

647-658

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S00280-018-3532-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gareth Evans

Gordon C. Jayson

P577

2018-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101127303

http://www.w3.org/2001/XMLSchema#string

P698

29464354

http://www.w3.org/2001/XMLSchema#string

P921

serous cystadenocarcinoma

P932

5854713

http://www.w3.org/2001/XMLSchema#string

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

about

P2860

P2860

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932